<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-149404</identifier>
<setSpec>0210-5020</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Evaluation of the effectiveness of an oil extract of rosehip in the prevention of epithelitis due toradiotherapy in patients with head and neck cancer</dc:title>
<dc:description xml:lang="en">Introduction. Epithelitis is a frequent side effect in radiotherapy treatments (RT). Objective. To evaluate the effectiveness of Rosehip Oil (ARM, Repavar) in the prevention of epithelitis in patients with head and neck cancer (HNC) treated with intensity modulated radiotherapy (IMRT). Material and methods. An interventionist, prospective, exploratory, controlled and open clinical study. Between May and October 2013, 28 patients were included in the study. After signing the informed consent form, the patients were provided with ARM to apply this twice daily from the beginning of the treatment. All of them had a prescribed dose of IMRT &amp;#8805; 60 Gy. They were evaluated weekly by nurses on the ward. A photographic monitoring of the skin with a registered grade of epithelitis and with signs of pain or other was carried out. The control group was formed of 34 consecutive patients with HNC treated with IMRT months prior to the study, whose skin treatment had been different products. Results. Both groups were comparable (age, sex, region and RT dose). In the study group (ARM), the number of treatments per patient (p = 0.3) and the natural days for treatment per patient (p = 0.38) were less; also, the number of patients who required  treatments and who suffered from radiodermitis of III-IV grade, were less. It is probable that the limited  specimen size may have influenced in the statistics. Conclusions. The effectiveness of ARM in the prevention of severe epithelitis in patients with HNC treated with RT is, at least, as effective (or more effective) as other and more common skin treatments. A randomized study would be required to confirm these findings (AU)</dc:description>
<dc:creator>Andueza Iriarte, María</dc:creator>
<dc:creator>Borda Rodríguez, María</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Introducción. La epitelitis es un efecto secundario frecuente en el tratamiento con radioterapia (RT). Objetivo. Evaluar la efectividad del aceite de rosa mosqueta (ARM, RepavarR) en la prevencion de epitelitis en pacientes con cancer de cabeza y cuello (CCC) tratados con radioterapia de intensidad modulada (IMRT). Material y métodos. Estudio clinico, intervencionista, prospectivo, exploratorio, controlado y abierto. Entre mayo y octubre de 2013 se incluyeron en el estudio 28 pacientes. Tras firmar el consentimiento informado, se les proporciono ARM para aplicarselo 2 veces/dia desde el inicio del tratamiento. Todo tenian prescritas dosis de IMRT &amp;#8805; 60 Gy. Enfermeria los evaluo semanalmente. Se realizo un seguimiento fotografico de la piel que registro el grado de epitelitis y la aparicion de dolor u otros. El grupo control lo constituyeron 34 pacientes consecutivos con CCC tratados con IMRT los meses previos al estudio, cuyo tratamiento topico se realizo con otros productos. Resultados. Ambos grupos son comparables (edad, sexo, localización y dosis RT). En el grupo de estudio (ARM) fue menor el numero de curas por paciente (p = 0.3) y los dias naturales de curas por paciente (p = 0.38); tambien fue menor el numero de pacientes que preciso curas y padecio radiodermitis grado III-IV. Probablemente, el limitado tamano muestral haya influido en la significacion estadistica. Conclusiones. La efectividad del ARM en la prevencion de la epitelitis grave en pacientes con CCC tratados con RT es al menos tan eficaz (probablemente mas) que la de los tratamientos topicos habituales. Seria deseable un estudio leatorizado para confirmar dichos hallazgos (AU)</dc:description>
<dc:source>Rev Enferm;39(1): 49-52, ene. 2016. tab, ilus</dc:source>
<dc:identifier>ibc-149404</dc:identifier>
<dc:title xml:lang="es">Evaluación de la efectividad de un extracto de aceite de rosa mosqueta (ARM) en la prevención de la epitelitis por radioterapia (RT) en pacientes afectos de cáncer de cabeza y cuello (CCC)</dc:title>
<dc:subject>^d13248^s22022</dc:subject>
<dc:subject>^d4927^s22042</dc:subject>
<dc:subject>^d13248^s22042</dc:subject>
<dc:subject>^d4927^s22022</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d12314^s22020</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d12294^s22012</dc:subject>
<dc:subject>^d12294^s22067</dc:subject>
<dc:subject>^d6409^s22054</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d12314^s22024</dc:subject>
<dc:subject>^d12294^s22054</dc:subject>
<dc:subject>^d6409^s22012</dc:subject>
<dc:subject>^d6409^s22024</dc:subject>
<dc:subject>^d6409^s22059</dc:subject>
<dc:subject>^d35251</dc:subject>
<dc:subject>^d28607</dc:subject>
<dc:subject>^d35934^s22038</dc:subject>
<dc:type>article</dc:type>
<dc:date>201601</dc:date>
</metadata>
</record>
</ibecs-document>
